DrugPatentWatch Database Preview
Nextwave Pharms Company Profile
What is the competitive landscape for NEXTWAVE PHARMS, and what generic alternatives to NEXTWAVE PHARMS drugs are available?
There are seven US patents protecting NEXTWAVE PHARMS drugs.
There are twenty-five patent family members on NEXTWAVE PHARMS drugs in fourteen countries.
Summary for Nextwave Pharms
| International Patents: | 25 |
| US Patents: | 7 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Nextwave Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nextwave Pharms | QUILLIVANT XR | methylphenidate hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 202100-001 | Sep 27, 2012 | RX | Yes | Yes | 8,778,390 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Nextwave Pharms | QUILLIVANT XR | methylphenidate hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 202100-001 | Sep 27, 2012 | RX | Yes | Yes | 8,956,649 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Nextwave Pharms | QUILLIVANT XR | methylphenidate hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 202100-001 | Sep 27, 2012 | RX | Yes | Yes | 9,040,083 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Nextwave Pharms | QUILLIVANT XR | methylphenidate hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 202100-001 | Sep 27, 2012 | RX | Yes | Yes | 8,465,765 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for NEXTWAVE PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Oral Suspension | 5 mg/mL | ➤ Subscribe | 2013-08-02 |
Non-Orange Book US Patents for Nextwave Pharms
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,491,935 | Modified release formulations containing drug-ion exchange resin complexes | ➤ Try a Free Trial |
| 8,597,684 | Modified release formulations containing drug-ion exchange resin complexes | ➤ Try a Free Trial |
| 8,747,902 | Modified release formulations containing drug-ion exchange resin complexes | ➤ Try a Free Trial |
| 8,202,537 | Modified release formulations containing drug-ion exchange resin complexes | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Nextwave Pharms Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2675438 | ➤ Try a Free Trial |
| Russian Federation | 2008140944 | ➤ Try a Free Trial |
| European Patent Office | 2428205 | ➤ Try a Free Trial |
| Spain | 2378573 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
